---

Número de diapositiva 1

1

Número de diapositiva 2

2

Número de diapositiva 3

3

Número de diapositiva 4

4

Número de diapositiva 5

5

Pivotal BOLERO-2 study: exemestane ± everolimus in ABC progressing after NSAIs

6

BOLERO-2: Final Analysis of Progression-Free Survival by (A) Local and (B) Central Assessment

7

Número de diapositiva 8

8

Número de diapositiva 9

9

Número de diapositiva 10

10

Número de diapositiva 11

11

Número de diapositiva 12

12

Número de diapositiva 13

13

First-line CDK inhibitors Study Designs

14

First line AI sensitive trials with CDK4/6 inhibitors

15

PALOMA-2 update

16

First-line CDK inhibitors Study Design in pre/peri-menopausal-only patients

17

Endocrine resistance CDK inhibitors Study Designs

18

Número de diapositiva 19

19

CDK inh-based phase III clinical trial-basedAdverse Events

20

Impact of dose delays and reductions on PFS with palbo-based therapy (MDACC experience)

21

What about older patients?

22

Número de diapositiva 23

23

Número de diapositiva 24

24

OtherTrials To Be Considered

25

MONARCH 1 (Phase II): Abemaciclib monotherapy in HR+/ HER- BC, after chemotherapy for advanced disease

26

MONARCH 1 (Phase II): Abemaciclib monotherapy in HR+/ HER- BC, after chemotherapy for advanced disease

27

TREnd study design

28

To Reverse Endocrine resistance (TREnd) trial: aims

29

Número de diapositiva 30

30

Duration of Clinical benefit

31

Progression free survival (PFS)

32

Predictive biomarkers for CDK4/6 inhibitors

33

Número de diapositiva 34

34

Integrating therapies for advanced cancer

35

PARSIFAL STRATEGY: First Line ER[+] MBCPhase II-randomized trial

36

CDK4/6 i + PI3K/mTOR i + AIs: ongoing trials

37

Número de diapositiva 38

38